Genetic Technologies Names New Director With No Current Equity Interest

Genetic Technologies ( (AU:GTG) ) has issued an update.

Genetic Technologies Limited has notified the ASX of the appointment of Jeffrey Michael Le Compte as a director, effective 24 March 2026, in compliance with listing rule 3.19A.1. The company disclosed that Le Compte currently holds no relevant interests in the company’s securities and has no disclosed interests in related contracts, indicating a neutral equity position at the time of his appointment.

The notice underscores the company’s adherence to corporate governance and disclosure obligations regarding director interests, which is important for maintaining transparency for shareholders and the market. The absence of any declared shareholdings or contract interests by the new director suggests no immediate change to the company’s capital structure or related-party exposure arising from this board appointment.

The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.

More about Genetic Technologies

Genetic Technologies Limited is a biotechnology company, though this filing does not provide detail on its specific products, services, or market focus. The company is listed on the ASX and is subject to Australian corporate and securities disclosure requirements, including director interest notifications under listing rule 3.19A.1.

Technical Sentiment Signal: Sell

Current Market Cap: A$5.67M

For an in-depth examination of GTG stock, go to TipRanks’ Overview page.